I've not personally had the opportunity to present to the Council of the Federation. I do know that the Health Care Innovation Working Group is currently focusing on generic drug prices, and there have been some interprovincial collaborations around the setting of pricing for generics.
The biggest challenge, frankly, in trying to harmonize the formularies and the contract negotiations between the provincial drug plans and the pharmaceutical manufacturers is the fact that our provincial drug plans vary so dramatically in structure. We have a huge variety of drug benefit plans in this country, and those differences, both in structure and administrative processes, in part, make it difficult for provinces to see a particular drug in the same light in terms of its priority for investment.
One of the next most important steps is to actually try to harmonize coverage, harmonize the structure of how we reimburse medicines, and then you can follow with the harmonization of what's actually being covered. But until you get commonality about who is covered and on what terms, it's difficult to get commonality on what's going to be listed, and particularly on the kind of reimbursement deal there will be.